|

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

RECRUITINGSponsored by Alnylam Pharmaceuticals
Actively Recruiting
SponsorAlnylam Pharmaceuticals
Started2026-01-09
Est. completion2030-10-23
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations4 sites

Summary

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Has a diagnosis of ATTR-CM
* Is initiating treatment with vutrisiran or another approved ATTR-CM therapy

Exclusion Criteria:

* Is enrolled in an interventional clinical trial

Conditions2

Heart DiseaseTransthyretin Amyloidosis With Cardiomyopathy

Locations4 sites

Florida

1 site
Clinical Trial Site
Naples, Florida, 34102

Massachusetts

1 site
Clinical Trial Site

New Jersey

1 site
Clinical Trial Site
New Brunswick, New Jersey, 08901

Tennessee

1 site
Clinical Trial Site

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.